...still being worked through in the consolidation of health tech (not all bad and to be expected), in bankruptcy court (23andMe), and the outright frauds in Federal courts (Done Global). To quote myself from June 2024: The investment scene in health tech and AI strongly resembles the Wild West days of airlines post-deregulation 30 years ago. Investor money in, now fleeing for the exits, whether the bankruptcy court or passing the hot potato to others with money. AI, of course, dwarfs the SPAC-driven health tech boom by a 1000X factor. And has the capacity to take down a world economy.... Continue Reading
Search Results for 23andme
TTA’s Hot July: 23andMe settles data breach payout, Done Health fraud principals sentenced,, Resmed sells MatrixCare, Pearl Health’s big raise, OpenAI’s 5% offer, more!
10-13 July 2026 A quieter post holiday week, but with one major sale and one substantial raise. Resmed sold off their MatrixCare post-acute software business to private equity, for substantially less than they paid for it seven years ago. The big raise was Pearl Health’s. Not so pearly were the substantial sentences and fines given to Done Health’s principals for out of control Adderall prescribing and fraud. Nor was 23andMe’s data breach settlement of $47 million while still in bankruptcy, or another Oracle software vulnerability. And OpenAI’s offer of 5% to the US government–good deal or Trojan Horse? But there’s... Continue Reading
News roundup: 23andMe settles with data breach victims for $46.75M, Neuralink implants #26 & first Canadian ALS patient, Resmed selling MatrixCare EHR for $490M, Teladoc now preferred telehealth provider for NBA players
...$100 for Statutory Cash Claims; and 5 years of Privacy & Medical Shield + Genetic Monitoring This is a second round settlement. The first settlement dates back to before the bankruptcy [TTA 17 Sept 2024] and was for $30 million. 23andMe filed for bankruptcy on 24 March 2025 after multiple buyout offers by Anne Wojcicki and others. Wojcicki eventually bought the company through her TTAM Research Institute in July 2025, then converted the holding company name to Chrome Holding Co. and ChromeCo, Inc. d/b/a 23andMe. What exactly Wojcicki intends to do with what’s left of 23andMe after emerging from bankruptcy... Continue Reading
Chutes & Ladders: Vendor protest filed against VA-OIT, Teladoc stock touted as ‘best buy’, Treehub ‘founder residency’ launches, AcuityMD raises $80M to near-$1B valuation
...studio with hands-on support, and an incubator community, with the capital of a venture fund. The Los Altos-based residency program is funded via the AI Health Fund and has some heavyweight names attached to it: Mary Minno, herself a former venture-backed founder now at Google, a brace of Stanford professors, Derek Minno of Point Capital, and two Wojcickis: Anne Wojcicki, founder of 23andMe, as Operating Partner and her mother, Esther Wojcicki, as a Founding Advisor. One wonders how Anne Wojcicki is faring in rebuilding 23andMe’s business and the 23andMe Research Institute; certainly they haven’t been shy about new products such... Continue Reading
Rock Health’s sunnier 2025: up 35% due to AI, but a tale of ‘have and have nots’
...now at a post-F financing. There is zero here about bankruptcies and reorganizations. No reference to the utter implosion of 23andMe and its shocking sale back to founder/CEO Anne Wojcicki. The impact of ACCESS and ELEVATE. There is also a good graphic analysis of two CMS models that may support digital health more comprehensively than previous value-based care models such as ACO shared savings. The first CMMI model, ACCESS, will be debuting in July and is a 10 year voluntary payment model for Original Medicare outcomes in chronic care management. It reduces barriers for digital health to profitably work with... Continue Reading
Editor Donna is back. Here’s the catchup.
...clever acronym of the spelled-out 23andMe. The Bankruptcy Court of Missouri approved the sale on 7 July and it closed on 14 July, after no further bids from Regeneron. Interestingly, none of the articles mention Wojcicki’s backers. 23andMe release, CNBC, HIPAA Journal. To this Editor, selling a company back to the CEO who had full financial control over the company but augured a $6 billion valued company into Chapter 11–nosediving after bad investments, a major data breach and turmoil around its data and privacy–is beyond absurdity. I’m surprised that the bankruptcy judge even permitted it given the history, but she... Continue Reading
Anne Wojcicki asks 23andMe bankruptcy court to reopen bidding on 12 June with fresh offer (updated with $305M bid)
...plenty of time for Anne Wojcicki to line up a fully backed bid for 23andMe to best any rival. Buyers were in the pipeline in early April, though not a single bidder rumored in the April ‘early line’ made it anywhere near the finals. 23andMe advisers, who would have access to 23andMe’s board and debtors, would also have access to information about Ms. Wojcicki’s resources. She made multiple lowball bids for 23andMe prior to the bankruptcy, including a bid with New Mountain Capital that disappeared in a week before even being presented to the board. The court, which could have... Continue Reading
News roundup: Hinge Health public @$32/share, lower valuation. Is WeightWatchers game over? Calibrate replaces CEO, new prez for Oak Street, NMC gets ‘Smarter’ rolling up 3 portfolio companies, another splash of investor ‘cold water’
...ask Anne Wojcicki of 23andMe. We close with a Gimlety view from three health investors. MedCityNews’ recent INVEST conference hosted three investors who opined on three important topics: Raffi Boyajian, Principal, Cigna Ventures; Aman Shah, Vice President of New Ventures, VNS Health; Dipa Mehta, Managing Partner, Valeo Ventures. Your Editor’s comments follow. Does every startup need to be AI-powered? Everyone may be pitching AI in their models, but it may not really mean anything. What really means something is building a good business first, then adding in AI to make it better, according to Aman Shah of VNS Health. When... Continue Reading
23andMe sold to Regeneron for $256M in court-supervised bankruptcy, sans Lemonaid. And is it worth it? (Updated 27 May for delisting)
Most of 23andMe bought for a lot more than one could have thought–and why? Yesterday, the board of 23andMe confirmed that they have a court-approved definitive agreement for the sale of their core genomics units to Regeneron Pharmaceuticals, Inc., a publicly traded (Nasdaq) biotech company based in Tarrytown, New York. The purchase price of $256 million includes the Personal Genome Service (PGS) and Total Health and Research Services business lines–but not Lemonaid. 23andMe will be operated as a wholly owned direct or indirect subsidiary. The asset auction was completed on 16 May. The acquisition by Regeneron remains subject to approval... Continue Reading
News roundup: Omada Health files for IPO, UPMC-Redesign partner on chronic pain management, OK and PA AGs warn 23andMe users to delete data, Verily to build Parkinson’s dataset, what payers paid for exec security
...Pitt and UPMC, who leads the clinics, is now medical director of Glimmer Health. CEO is Alissa Meade, previously CEO of Together Senior Health, sold last year to Linus Health according to her LinkedIn profile. UPMC release “Delete Your 23andMe Data!” say Oklahoma’s and Pennsylvania’s Attorneys General. Oklahoma’s AG Gentner Drummond finally got the news (via the wind whistling down the plains?) along with Pennsylvania’s AG Dave Sunday that 23andMe went bankrupt in March and it, or parts, are up for sale. The two AGs advise citizens of their respective states to delete their data, instruct 23andMe to destroy their... Continue Reading
Most Recent Comments